GSK announced on Monday that the European Commission had approved the marketing of its Jemperli immunotherapy for the first-line treatment of endometrial cancer.

In a press release, the British company explains that the Brussels authorization concerns the combination of Jemperli and chemotherapy in the treatment of advanced or recurrent endometrial cancer with dMMR/MSI status.

This is the first immunotherapy approved in this indication.

GSK reports that the European Union has also decided to consider as definitive the conditional monotherapy authorization it had previously granted to Jemperli in the second-line treatment of endometrial cancer.

Initially discovered by the American company AnaptysBio, Jemperli had been the subject of a licensing agreement since 2014 with Tesaro, since acquired by GSK, which is now responsible for its development and commercialization.

Copyright (c) 2023 CercleFinance.com. All rights reserved.